(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 January 2014 (03.01.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/003536 A9

(51) International Patent Classification:
C07K 19/00 (2006.01) *A61P 31/00* (2006.01)
A61K 38/00 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/MY2013/000114

(22) International Filing Date:
25 June 2013 (25.06.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PI 2012002923 26 June 2012 (26.06.2012) MY

(71) Applicant: **BIOVALENCE SDN. BHD.** [MY/MY]; 21, Jalan SS25/34, Taman Mayang Industrial Park, Petaling Jaya 47301 (MY).

(72) Inventors: **SEKARAN, Shamala Devi K C**; 17 Jin 10/10 F, Petaling Jaya 46000 (MY). **ROTHAN, Hussin A.**; 3-7-7 OUG Condominium, Jin 3A/155, Kuala Lumpur 58000 (MY). **UNG, Eng Huan**; No. 2, Lorong Ujana Kingfisher 9, Kingfisher Ujana 88450, Kota Kinabalu, Sabah (MY). **ABU BAKAR, Ag. Muhammad Sagaf**; P.O. Box 81, Pos Mini, Central Plaza, 88300 Kota Kinabalu, Sabah (MY).

(74) Agents: **JEFFREY, Fiona Teresa** et al.; Marks & Clerk (Malaysia) SDN BHD, PO Box 11182, 50738 Kuala Lumpur (MY).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

[Continued on next page]

(54) Title: DOSAGE REGIME OF FUSION COMPOUNDS

```
   1 ATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAGCCGGCG
   1  M  K  Y  L  L  P  T  A  A  A  G  L  L  L  L  A  A  Q  P  A
  61 ATGGCCATGGGGCGTATTTGCCGTTGCATTTGCGGCCGTGGCATTTGCCGCTGCATCTGT
  21  M  A  M  G  R  I  C  R  C  I  C  G  R  G  I  C  R  C  I  C
 121 GGCGTGCCGGGTGTTGGTGTTCCGGGTGTGGGTGGTGCGACCGGATCCGATGTGAACTTT
  41  G  V  P  G  V  G  V  P  G  V  G  G  A  T  G  S  D  V  N  F
 181 GATCTGAGCACCGCGACCGCGAAAACCTATACCAAATTCATCGAAGATTTTCGTGCGACC
  61  D  L  S  T  A  T  A  K  T  Y  T  K  F  I  E  D  F  R  A  T
 241 CTGCCGTTTAGCCATAAAGTGTATGATATCCCGCTGCTGTATAGCACCATTAGCGATAGC
  81  L  P  F  S  H  K  V  Y  D  I  P  L  L  Y  S  T  I  S  D  S
 301 CGTCGTTTTATTCTGCTGGATCTGACCAGCTATGCGTATGAAACCATTAGCGTGGCGATT
 101  R  R  F  I  L  L  D  L  T  S  Y  A  Y  E  T  I  S  V  A  I
 361 GATGTGACCAACGTGTATGTGGTGGCGTATCGTACCCGTGATGTGAGCTACTTTTTCAAA
 121  D  V  T  N  V  Y  V  V  A  Y  R  T  R  D  V  S  Y  F  F  K
 421 GAAAGCCCGCCGGAAGCGTACAACATTCTGTTTAAAGGCACCCGTAAAATTACCCTGCCG
 141  E  S  P  P  E  A  Y  N  I  L  F  K  G  T  R  K  I  T  L  P
 481 TATACCGGCAACTATGAAAACCTGCAGACCGCGGCGCATAAAATTCGTGAAAACATCGAT
 161  Y  T  G  N  Y  E  N  L  Q  T  A  A  H  K  I  R  E  N  I  D
 541 CTGGGCCTGCCGGCCCTGAGCAGCGCGATTACCACCCTGTTTTATTATAACGCGCAGAGC
 181  L  G  L  P  A  L  S  S  A  I  T  T  L  F  Y  Y  N  A  Q  S
 601 GCGCCGAGCGCGCTGCTGGTGCTGATTCAGACCACCGCGGAAGCGGCGCGTTTTAAATAT
 201  A  P  S  A  L  L  V  L  I  Q  T  T  A  E  A  A  R  F  K  Y
 661 ATTGAACGCCACGTGGCGAAATATGTGGCGACCAACTTTAAACCGAACCTGGCCATTATT
 221  I  E  R  H  V  A  K  Y  V  A  T  N  F  K  P  N  L  A  I  I
 721 AGCCTGGAAAACCAGTGGAGCGCCCTGAGCAAACAAATTTTCTGGCCCAGAACCAGGGC
 241  S  L  E  N  Q  W  S  A  L  S  K  Q  I  F  L  A  Q  N  Q  G
 781 GGCAAATTTCGTAATCCGGTGGATCTGATTAAACCGACCGGCGAACGTTTTCAGGTGACC
 261  G  K  F  R  N  P  V  D  L  I  K  P  T  G  E  R  F  Q  V  T
 841 AATGTGGATAGCGATGTGGTGAAAGGCAACATTAAACTGCTGCTGAACAGCCGTGCGAGC
 281  N  V  D  S  D  V  V  K  G  N  I  K  L  L  L  N  S  R  A  S
 901 ACCGCGGATGAAAACTTTATTACCACCATGACCCTGCTGGGCGAAAGCGTGGTGGAATTC
 301  T  A  D  E  N  F  I  T  T  M  T  L  L  G  E  S  V  V  E  F
 961 CCGTGGGCGCTGTGGAAAACCATGCTGAAAGAACTGGGCACGATGGCGCTGCATGCGGGT
 321  P  W  A  L  W  K  T  M  L  K  E  L  G  T  M  A  L  H  A  G
1021 AAAGCGGCGCTGGGTGCGGCAGCGGATACCATTAGCCAGGGCACCCAGGTTCCGGGCGTG
 341  K  A  A  L  G  A  A  A  D  T  I  S  Q  G  T  Q  V  P  G  V
1081 GGCGTTCCGGGCGTTGGTAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGA
 361  G  V  P  G  V  G  K  L  A  A  A  L  E  H  H  H  H  H  H  *
```

(57) Abstract: Use of at least one fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, polypeptide B; and at least one polypeptide A which is a antimicrobial peptide and/or at least one Cationic AntiMicrobial Peptide, polypeptide C for the preparation of a medicament for treating a cancer and/or a microbial infection wherein the medicament is suitable for oral administration pre food intake.

WO 2014/003536 A9

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
30 January 2014

(15) Information about Correction:
see Notice of 30 January 2014